02 8011 4217, 0416 974 651  info at scenar.com.au

Electric Device For Bisphosphonate-Induced Osteonecrosis

Abstracts of the 2008 International MASCC/ISOO Symposium

Support Care Cancer (2008) 16:619–756  DOI 10.1007/s00520-008-0457-6

02-026
Electric Device For Bisphosphonate-Induced Osteonecrosis
Boris Zaidiner1, Ilia Baranovsky2, Darya Leontyeva3, Irene Petrenko2 1Regional Cancer Hospital, Out-patient Care, Rostov-on-Don, Russia, 2Medical Unit, Laboratory of Immunology, Rostov-on-Don, Russia, 3Research Cancer Center, Laboratory of Biophysics, Rostov-on-Don, Russia, 4Medical Unit, Laboratory of Endocrinology, Rostov-on-Don, Russia

Objectives: Osteonecrosis of the jaw (ONJ) is serious adverse event in patients (pts) who administer bisphosphonates for metastatic bone disease. Its management outcome remains poor. To improve results of conventional treatment we’ve used electric therapy device (“SCENAR”, US Patent N 5257623) which was tested in some fields of supportive care. This is attempt to show our experience in SCENAR-technology usage for ONJ.

Methods: In preliminary trial 28 pts with bisphosphonaterelated
ONJ (mean age 59,2 years, range 36–81 years) were enrolled; nosologic forms: breast cancer 9 pts, prostate cancer 7 pts, lung cancer 6 pts, multiple myeloma 3 pts, renal cell cancer 2 pts, far-advanced malignancy without verified primary site – 1 patient. Clinical picture was presented with pain (at rest & jaw movement), swelling, exposed bone; suppuration was noted in 3 pts. Dental surgery prior to bisphosphonate therapy was in almost all pts. After signing the informed consent every patient 15 SCENAR-procedures was performed in addition to conventional supportive care. During these procedures various cutaneous and mucosal areas were treated, their choice was based upon patient’s complaints, their technique was described earlier.

Results: In 17 pts (60,7%) positive results were achieved. They felt better, had partial pain relief (the relief ratings on VAS were significantly improved). In 5 of 19 pts with exposed oral maxillofacial bone the lesions had tendency to heal; in 2 of these 5 pts radiographic changes have become less obvious.

Conclusions: In our study group adding SCENAR to standard therapy appeared to result in more promising outcome then available literature data were presented. Further research is necessary to establish its exact position in multimodal approach for bisphosphonate-related ONJ.

 

DOWNLOAD

SCENAR IN ARTERIAL HYPERTENSION

SCENAR IN ARTERIAL HYPERTENSION

N.G. Sivirinova, A.V. Tarakanov, L.V. Klimova
Rostov State Medical University, Rostov-on-Don

All around the world, and in Russia particularly, arterial hypertension is one of the most important and current medical and social problem. It is the key risk factor for most cardio-vascular diseases, myocardial infarctions and strokes that greatly contribute to high mortality in the country. Hypertension affects about 40% of adults.

Sleep is one of the factors that influences the BP level and regulates activity of our body. However, we have lack of scientific data on how sleep influences on hypertension. Today sleep disorders can be treated by medicines, as well as by non-drug therapies. Electric pulse stimulation with SCENAR is one of the non-drug modalities for those who suffer from sleep disorders.

Research objective was to study the effect of SCENAR-therapy on blood pressure parameters and make a subjective assessment of sleep in patients with hypertension.

We gave questionnaire on sleep disorders to hospital patients and on its basis selected 60 patients to participate in the research. Using random sampling, we have divided the patients into 2 groups:

Group 1 – 30 patients (18 men and 12 women), mean age 58.2±1.2 years. This group was control group.

Group 2 – 30 patients (17 men and 13 women), mean age 54.1±1.4 years. This group received complementary therapy with SCENAR.

On examination patients had the following values:

Group 1: systolic blood pressure (SBP) – 1792±20 mmHg, diastolic blood pressure (DBP) – 91.0±1.4 mmHg, heart rate (HR) – 90.0±1.0 bpm.

Group 2: systolic BP – 178.0±2.3 mmHg, diastolic BP – 88.0±2.2 mmHg, heart rate (HR) – 83.9±2.2 bpm.

In both groups patients received common hypertensive medicines, and in Group 2 common therapy was complemented with SCENAR-stimulation (twice a day for two weeks). SCENAR-therapy included stimulation of the collar zone with spaced electrodes using the CHANS-SCENAR-02 device following specific pattern and stimulation in the projection of patient’s complaint with the built-in device electrode. All the patients refused form taking any drugs for treating sleep disorders 2-3 months before the research. The effectiveness of antihypertensive therapy and SCENAR-treatment was assessed by comparing sleep and BP parameters at the end of the hospital treatment. We also evaluated the results of BP Holter monitoring.

Results. By the end of the second week of the treatment we marked that clinical symptoms of arterial hypertension decreased or disappeared, and main hemodynamic parameters changed significantly. The analysis of treatment with SCENAR and without showed that patients from Group 1 and 2 manifest the decrease of SBP by 24.3 and 24.5%, DBP by 10.3 and 13,1 %, HR by 17.3 and 16.0%, double production by 37.3 and 36.0% respectively. Comparative analysis showed no significant difference in the abovementioned BP parameters in patients who received SCENAR-treatment. However, it not enough to use only integral BP parameters to evaluate the effectiveness of SCENAR as all the mechanisms of the hemodynamic adaptive response are not investigated enough.

We have analyzed the subjective assessment of sleep and identified that appropriate antihypertensive therapy in Group 1 has almost no effect on characteristics of sleep. Total score changed from 18.3 to 19.4 points. While including SCENAR into the treatment contributes to significant and positive changes in pre-, intra- and postsomnia processes, faster falling asleep and longer duration of sleep, fewer night wake-ups, better quality of sleep, less nightmares, and better quality of morning wake-ups. Total score changed from 11 to 24 points. That signs that patients cured the insomnia associated with the hypertension. However, we can’t state for sure whether sleep disorders are primary or secondary when accompanied with arterial hypertension.

Analysis of Holter monitoring showed different results of SCENAR-therapy. We marked that average pulse pressure in Group 1 and 2 decreased by 17.8 and
41.5%, daily index of SBP significantly decreased by 26.3 and 52.4%, daily index of DBP by 34.2 and 40.8% respectively. The nighttime effect was very positive: in Group 1 and 2 average SBP decreased by 21.3 and 30.7% (P<0,05), average DBP by 18.1 and 21.1%, SBP variability decreased by 28.2 and 58.0% (P<0,05), DBP variability decreased by 14 and 32.2% (P<0,05) respectively.

Findings. We have identified that patients after SCENAR manifest normalization and stabilization of blood pressure, if compared with the control group, improved pressure parameters according to Holter monitoring, as well as improved sleep parameters. The associated pathology didn’t get worse. SCENAR is very effective and safe complementary treatment modality, therefore it could be considered as non-drug therapy that could be recommended for hypertonic patients with sleep disorders.

Using SCENAR-therapy for treating hypertension crisis in pre-hospital period

Published in: Reflexology – 2008 – No. 3-4 – pp. 23-26

Authors: Los E.G., Tarakanov A.V., Hatisova E.V., Department of Emergency Medical Aid at the State University – Rostov-on-Don

Title: Using SCENAR-therapy for treating hypertension crisis in pre-hospital period

Key words: SCENAR-therapy, hypertension crises, pre-hospital period

Annotation: The article shows the effectiveness and safety of SCENAR-therapy when used for uncomplicated hypertension crises in pre-hospital period (n=97), with gradual reliable cardiac rate fall, decrease of the parameters of arterial tension, and decreased frequency of complaints in 20 minutes after the manipulation. The effectiveness of SCENAR-therapy gives evidence of human body’s existing powerful self-regulatory abilities to repair its damaged functions, and the use of this method is an alternative treatment for some cases in this category of patients.

 

DOWNLOAD

 

The use of electronic biofeedback for the management of post-herpetic neuralgia-a report of 3 cases.

 2007 Sep;66(9):232, 234.

The use of electronic biofeedback for the management of post-herpetic neuralgia–a report of 3 cases.

Abstract

The purpose of these case reports is to describe treatment of three consecutive patients with post-herpetic neuralgia using a bioelectronical device (SCENAR). The instrument is approved as a Class II device in the United States. The electrode of the device was stroked gently over the involved skin area for up to 15 minutes per session. No more than 5 sessions over a 3-week period was required. All patients experienced substantial relief of pain from the first treatment. One patient required only 1 treatment lasting 10 minutes. The other 2 patients required 4 to 5 treatments over a 3-week period. One patient required a treatment for skin itch after one year with a follow up period of 6 months to 24 months. An electronic biofeedback device (SCENAR) may be successfully utilized in the management of post-herpetic neuralgia.

Effect of arthrophon with use of Transcutaneous Neurostimulation on values of lipid peroxidation at complex post-surgical therapy in patients with purulent appendicular peritonitis

Effect of arthrophon with use of Transcutaneous Neurostimulation on values of lipid peroxidation at complex post-surgical therapy in patients with purulent appendicular peritonitis

Publication: Pharmacology – Practical Healthcare, Issue No: 7, September 2007, St. Pertersburg, Russia

Authors: Luspikayan S.H., Tarakanov A.V., Voronkin D.A.)
State medical university of Rostov, 29, Nahichevan st., Rostov-on-Don, 344022

The tumour necrosis factor-alpha (TNF) plays a significant part in inflammatory destruction of pathogenesis.

Purpose – to explore the influence of arthrophon in respect of its bipathic effect combined with transcutaneous neurostimulation (SCENAR-therapy) on the state of lipid peroxidation, values of endogenous intoxication at treatment of patients with purulent appendicular peritonitis in post-surgical period.

Materials and methods: 58 patients were examined who were operated for purulent peritonitis. All the patients were treated with conventional intensive therapy. In group 1 (n =38) treatment combined with SCENAR was performed. In group 2 (n=20), four tablets per day of arthrophon were additionally prescribed, plus 5 procedures of SCENAR-therapy. The control (n=36) – healthy donors comparable as age and sex. Evaluation of efficiency was performed according to clinical and laboratory data on the first and fifth day from the start of the treatment. Application of arthrophon led to decrease of the level of myeloperoxidase with 50.1% (p<0.001). The activity of catalase increased with 41% compared with the initial background (p<0.02) and reached the control group. In both groups, statistically reliable decrease of malondialdehyde (MDA) was noted as well as decrease of diene-conjugates on the 5th day of the treatment. The level of intoxication was defined according to the fraction of medium-mass molecules in blood plasma. After a five-day course of therapy in the first group the contents of medium-mass molecules (280) decreased with 28.8% (p<0.01), in the second group – with 39% (p<0.001). In the second group, decrease of medium-mass molecules was noted – 30.3% (p<0.05), in the first group a reliable change of this value was not noted. On the background of arthrophon and SCENAR-therapy, the level of circulating immune complex dramatically decreases 5 days after the treatment – 40.3% (p<0.01).

Conclusions: arthrophon combined with SCENAR-therapy proves to be an effective therapeutic means for post-surgical period in patients with purulent appendicular peritonitis. A significant decrease of clinical symptoms of the disease was noted, as well as normalization of paraclinical values. The combined therapy allows to correct faster and more efficiently the extent of endogenous intoxication, which were evaluated with reliable decrease of some fractions of medium-mass molecules and circulating immune complex. Arthrophon and SCENAR-therapy combined with basic intensive therapy in post-surgical period in patients with purulent appendicular peritonitis decreased the intensity of processes of lipid peroxidation on the 5th day, increased anti-oxidant protection and improve the function condition of cellular membranes.

SCENAR-technology for chemotherapy-induced neurotoxicity

Abstracts of the 20th Anniversary International MASCC/ISOO Symposium

Support Care Cancer (2007) 15:651–797 DOI 10.1007/s00520-007-0262-7

P-153
SCENAR-technology for chemotherapy-induced neurotoxicity
B. Zaidiner1, N. Lyan2, I. Baranovsky3, I. Petrenko4 1Regional Cancer Hospital, Department of Ambulatory Care, Rostov-on-Don, Russia 2Medical Unit BIOCAR, Rostov-on-Don 3Medical Unit “Zdorov’e”, Rostov-on-Don 4Pharmacy Unit, Rostov-on-Don

Background: Drug toxicity is the major limiting factor in chemotherapy (CT) of malignancies. Anti-cancer agents produced a broad range of side effects that diminish patients’ quality of life and limit their ability to tolerate the pIanned treatment regimen. The supportive care for these patients is routinely based on chemoprotectants: mesna, amifostine etc., the physical factors in this context are less common.

Our previous works have shown the efficacy of SCENARdevice (US Patent 1 5257623) for pain relief and some other issues. We’ve tried to present our experience in usage of SCENAR-technology for CT-induced neurotoxicity.

Materials and methods: In this preliminary trial 36 pts (mean age 46.8±7.6 years) with advanced ovarian cancers were observed. All patients were treated with Pt derivatives (oxaliplatin, cisplatin), whose cumulative dose have being ?540 mg/m*; they suffered from burning & aching pains and paresthesias; sensory deficit was noted. After signing the informed consent every patient 15 SCENAR-procedures were done in addition to conventional supportive therapy. These procedures consisted of treatment of various cutaneous areas which were chosen as applied patient’s complaints. They were conducted daily, their technique was described earlier.

Results: We’ve achieved positive results in 23 patients (63.9%) who felt better, their pain relief ratings on Visual Analogue Scale were significantly improving, part of them could refuse or reduce analgesic usage), the sensory disturbances were partially restored. The reasonable results were noted in 8 (22.2%) and bad in 5 (13.9%) patients. The analgesic reducing helped to prevent their side-effects.

Conclusion: SCENAR may be useful for patients with  anticancer toxicity as a part of comprehensive therapeutic program. Its exact position in variety of clinical situations will be established in the randomized placebo-controlled trial which is being conducted now. We conceive our results to be promising for continued study of SCENAR technology in supportive care.

 

DOWNLOAD

SCENAR THERAPY FOR MYOFASCIAL PAIN SYNDROME

WACBE World Congress on Bioengineering 2007

Bangkok, THAILAND

SCENAR THERAPY FOR MYOFASCIAL PAIN SYNDROME

INBOHAN,MD

Department of Neurosurgery, Pochon CHA University, College of Medicine, 351, Yatap-dong, Bundang-Gu, Sungnam, 463-712, Korea

RYOONGHUH,MD

Department of Neurosurgery, Pochon CHA University, College of Medicine, 351, Yatap-dong, Bundang-Gu, Sungnam, 463-712, Korea

ABSTRACT

SCENAR device generates electrical impulses that are physiologically similar to neuroimpulses. Pain is the most common complaint to be dealt with in the SCENAR therapy by block of transmission of the pain impulses in the nerve endings of the peripheral nerve fibers, pain focus suppression of brain cortex, and reduction of the edema around the nerve fibers leading to reduction of pressure effect. We investigated the usefulness and effectiveness of SCENAR therapy in patients with MPS. SCENAR therapy was performed in 202 patients with MPS. The ratio of male to female was 1:4.5. The mean age was 47.3 years (range: 18-75 years). The mean follow up period was 6 months (range: 3 months-16months). The visual analogue scale (VAS) was used to assess the effectiveness of SCENAR therapy. The overall improvement of pain was 89%. Especially, the improvement of acute pain was good, and all patients presenting MPS was satisfactory. This study suggests that SCENAR therapy would be very useful new method to deal with MPS.

INTRODUCTION

Myofascial pain syndrome (MPS) is a local or regional musculoskeletal pain disorder that may involve either a single muscle or a muscle group. It develops due to any number of causes including sudden trauma to musculoskeletal tissues. It seems to occur in virtually everyone’s lives at some point but becomes chronic and intractable in some cases. MPS has a significant impact on functional status, restricting occupational activities with marked socioeconomic repercussions. The management of MPS encompasses a range of different interventions, including trigger point injections, drug, exercise, patient education, physiotherapy, and alternative therapies. The treatment goals are to relieve pain, reduce muscle spasm, improve strength and range of motion, promote early return to activity, encourage active coping strategies, and ultimately improve functional status. The risks and benefits of these treatments vary. SCENAR standing for Self Controlled Energo Neuro Adaptive Regulator was first invented in Russia in mid 80s. We experienced the clinical benefit provided by SCENAR therapy and demonstrated the effectiveness of SCENAR therapy.

ISBN: 978-81-904262-8-2(RPS) ©2007 WACBE’07. All rights reserved.

METHODS

The study population was composed of 202 patients with MPS. The ratio of male to female was 1: 4.5. The mean age was 47.3 years (range: 18-75 years). SCENAR therapy was performed between August 2005 and December 2006. The mean frequency of this treatment was 3 times a week and the mean duration time per each treatment was 5 minutes. The mean follow up period was 6 months (range: 3 months- 16 months). The visual analogue scale (VAS) was used to assess the effectiveness of SCENAR therapy.

RESULTS

The overall improvement of pain was 89%. Especially, the improvement of acute pain was good, and all patients presenting MPS was satisfactory.

DISCUSSIONS

SCENAR was first invented in Russia in mid 80s under space and military research program. SCENAR device generates electrical impulses that are physiologically similar to neuroimpulses. In respond to a SCENAR impulse, reflex biofeedback proceeds at real time and biological speed. By continuously using biofeedback, the SCENAR modifies each successive input signal to either amplify or dampen the form of the pathological signals that exist in the body. Pain is the most common complaint to be dealt with in the SCENAR therapy by block of transmission of the pain impulses in the nerve endings of the peripheral nerve fibers, pain focus suppression of brain cortex, and reduction of the edema around the nerve fibers leading to reduction of pressure effect. SCENAR therapy is contraindicated in patients with cardiac pacemakers due to the potential of interfering with pacemaker activity.
SCENAR therapy can be differentiated from TENS. They use electrical stimulation. However, the pulse of the SCENAR device is bipolar and has short triangle and high amplitude. The electrodes of SCENAR device were fixed. Our study suggests that SCENAR therapy would be very useful method to deal with MPS.

REFERENCES
[1] Verhoeven, K., Dijk, J.V. Decreasing pam in electrical nerve stimulation. Clinical
Neurophysiology., 7/7(2006),972-978.
[2] Khadilkar, A., Milne, S., Brosseau, L., Wells, G, et al. Transcutaneous electrical nerve stimulation for the treatment of chronic low back pain: a systemic review. Spine., 30 (2005), 2657-266

Proa of the 3rd WACBE World Congress on Bioengineering 2007

 

SCENAR THERAPY FOR LYMPHEDEMA

WACBE World Congress on Bioengineering 2007

Bangkok, THAILAND

SCENAR THERAPY FOR LYMPHEDEMA

R YOONG HUH, MD
Department of Neurosurgery, Pochon ???University, College of Medicine, 351, Yatap- dong, Bundang-Gu,Sungnam, 463-712, Korea
INBOHAN, MD Department of Neurosurgery, Pochon ???University, College of Medicine, 351, Yatap- dong, Bundang-Gu, SUngnam, 463-712, Korea

ABSTRACT
SCENAR standing for Self-Controlled Energo Neuro-Adaptive Regulator was first invented in mid 80s. The goal of therapy for Jymphedema is lymphatic drainage. We investigated the usefulness and effectiveness of SCENAR therapy in patients with lymphadema. SCENAR therapy was performed in 28 patients with lymphadema. All patients were female and were performed radiation treatment due to breast cancer in-7 patients, cervical cancer in 13 patients, and ovarian cancer in 8 patients. The mean age was 53.7 years (range: 37-65 years). The mean frequency of SCENAR therapy was 4 times a week and the mean duration time per each treatment -was 8 minutes. The mean follow up period was 7 months (range: 3 months-18months). The circumference of affected extremities was measured before and after treatment. The overall improvement of lymphadema was 79% and the pain associated with lymphadema also improved in 85 % of patients. This study suggested that the SCENAR device impulse helps fluid come out of the lymphatic system and improves the microcirculation. SCENAR device also eliminates inflammatory process in the lymph nodes. Therefore, – SCENAR therapy would be very useful method to deal with lymphedema.

ISBN: 978-8l-904262-8-2(RPS) ©2007 WACBE’07. Ail rights reserved.

INTRODUCTION

Lymphedema is a debilitating progressive condition with no known cure. The underlying problem is lymphatic dysfunction, resulting in an abnormal accumulation of interstitial fluid containing hig h molecular weight proteins. It is usually observed following breast cancer surgery, particularly among those who undergo radiation therapy following axiallary lymphadenectomy. In a disease state, the lymphatic transport capacity is reduced. This causes the normal volume of interstitial fluid for mation to r\exceed the rate of lymphatic return, resulting in the stagnation of high molecular weigh t proteins in the interstitium. Surgical treatment is palliative, not curative, and it does not obviate the need for continued medical therapy.

SCENAR standing for Self Controlled Energo Neuro Adaptive Regulator was first invented in Russia in mid SOs. We experienced the clinical benefit provided by SCENAR therapy for patients with lymphedema and demonstrated the effectiveness of SCENAR therapy.

METHODS

SCENAR therapy was performed in 28 patients with lymphadema. All patients were female and were performed radiation treatment due to breast cancer in 7 patients, cervical cancer in 13 patients, and ovarian cancer in 8 patients. The mean age was 53.7 years (range: 37-65 years). The mean frequency of SCENAR therapy was 4 times a week and the mean duration time per each treatment was 8 minutes. The mean follow up period was 7 months (range: 3 months-18months). The circumference of affected extremities was measured before and after treatment.

RESULTS
The overall improvement of lymphadema was 79% and the pain associated with lymphadema also improved in 85 % of patients.

DISCUSSIONS
Lymphedema is a notoriously debilitating progressive condition caused by damage or removal of regional lymph nodes through surgery, radiation, infection, or tumor invasion. The goal of therapy is lymphatic drainage. SCENAR device generates electrical impulses that are physiologically similar to neuroimpulses. In respond to a SCENAR impulse, reflex biofeedback proceeds at real time and biological speed. By continuously using biofeedback, the SCENAR modifies each successive input signal to either amplify or dampen the form of the pathological signals that exist in the body.
Although the pathophysiology of lymphedema is still unclear, it has been reported that protein and fluid accumulation initiates a marked inflammatory reaction in the interstitium. Macrophage activity is increased, resulting in destruction of elastic fibers and production of fibrosclerotic tissue.
The result of this inflammatory reaction is a change from the initial edema to the brawny nonpitting edema characteristics of lymphedema. This study suggested that the SCENAR device impulse helps fluid come out of the lymphatic system and improves the microcirculation. SCENAR device also eliminates inflammatory process in the lymph nodes. Therefore, SCENAR therapy would be very useful method to deal with lymphedema.

REFERENCES
[1] Verhoeven, K., Dijk, J.V. Decreasing pain in electrical nerve stimulation. Clinical Neurophysiology., 7/7(2006),972-978.
[2] Khadilkar, A., Milne, S., Brosseau, L., Wells, G, et al. Transcutaneous electrical nerve stimulation for the treatment of chronic low back pain: a systemic review. Spine., 30 (2005), 2657- 266

Proc. of the 3rd WACBE World Congress on Bioengineering 2007

NEUROREGULATORS IN THE TREATMENT OF DISEASES OF ANIMALS

Russian Academy of Natural Science

Publication: Scientific journal “Success of Modern Natural Science” #5, 2007

Article name: NEUROREGULATORS IN THE TREATMENT OF DISEASES OF
ANIMALS

Authors: A.D.Polyakov, G.I.Zaitsev, Cameroon State Agricultural Institute Kemerevo, Russia

Nowadays electric neuroregulators are widely used for the medical purposes. Electric neuroregulators are the devices able to impact an alive organism with the electric signals of a certain form, duration and capacity. Among others they include SCENAR (a selfchecking energy-neuro-adaptive regulator of a psychosomatic homeostasis) and DENAS (a two band electric – neuro – adaptive stimulator) [1]. The family of these devices is used both for diagnostics of pathologies, and for treatment of a wide spectrum of diseases.

Upon turning on the device its electronic blocks form impulses with the set amplitude and frequency of recurrence. The external electrodes get a signal consisting of a trapezoid impulse of a negative polarity followed by the forced/induced damped/decaying fluctuations the first half-cycle of which is positive. The form of such a signal is close to biosignals in muscular tissues and therefore it does not cause any negative consequences upon applying. The duration of the first half-cycle of fluctuations is a key parameter for an estimation of a body conditions (norm-pathology), connected with a zone of treatment. It also indicates the moment of the treatment/impact discontinuing. With this purpose the forced/induced fluctuations are detected and are treated in a certain way by means of the block measuring the duration and speed of change in the first half-cycle fluctuations. Initially the first half-cycle of fluctuations is allocated from a full signal, then the duration of each first impulse of a series is measured and, finally, the changes in duration which occurred in unit time are evaluated. If the duration of a half-cycle does not change within 5-10 seconds of an impact/applying, that means the projected body is all right, and the device “makes a decision” to stop impact in this spot. And if the duration in the beginning of applying exceeds the duration in the other zones in 1.5-2 times the neuroregulator “comes to conclusion” that there is an inflammatory process in this particular body.

And finally, if the duration of the first half-cycle, on the contrary, appeared to be 1.5-2 times less, than in the other zones, that means that the body undergoes degenerate phenomena. The device can increase quantity of impulses in a series, if the speed of the changes of the first half-cycle duration in 5-10 seconds turned to be less than a set one.
As soon as the organism quits reacting to the impact, SCENAR stops electro stimulation. Inflammatory processes in a mammary gland (mastitis) are extremely diverse in their etiology, and depend on physiological condition of an animal and various external factors. Mastitis results in blood circulations and lymph kinesis disorders, low/poor permeability of capillary membranes and vessels, change biochemical processes in tissues. The day after a double 10-minute SCENAR treatment cows with an acute serous mastitis show the general condition and appetite improvement, the temperature normalization, no pain or swelling of affected lobes of an udder, the qualitative structure of milk improvement. Dairy/milk production/efficiency recovers up to 100 %. Clinical recovery of all sick animals is complete after 3-4 days. There are no relapses the following days.

In the case of the mastitis accompanied by a proventriculus atony, endometritis, the medical effect occurs on the fifth day without the further relapses. The treatment appears to be effective and for an acute catarrhal mastitis and other diseases associated with it, such as endometritis, gastroenteritis, atone, etc. Recovery is complete within three days with a full restoration of the dairy/milk production/efficiency. The use of the traditional methods doesn’t lead to the medical effect.

The next day after SCENAR treatment cows with an acute purulent catarrhal mastitis show the general condition and appetite improvement, the temperature normalization, no pain of affected lobes/quarters of an udder, the quality of milk improvement. In the case of the hemorrhagic mastitis the complete recovery occurs on the third day without the further relapses. The clinical recovery after fibrinogen us mastitis takes 10 days, and dairy/milk production/efficiency recovers up to 97% and using traditional methods of treatment up to only 55 %. In case with chronic catarrhal and purulent catarrhal mastitis the animals’ healing occurs on the 9th day. Dairy/milk production/efficiency recovers up to 95%.

The one-sided therapy on corresponding inflamed lobes for 10 minutes is sufficient under one-sided affection of parts of an udder. When a cow has both right and left lobes of an udder inflamed as well as mastitis with accompanying diseases, it is necessary to treat each lobe of an udder, sacral and lumbar sections in the morning and at night before milking for 3 minutes on each spot.

When using SCENAR to treat purulent- catarrhal endometritis the bioelectric potentials of muscles of a uterus recover fast, spasm of a cervix decreases. SCENAR therapy appears to be effective on acute and purulent- catarrhal endometritis after calving. Animals recover on the 4th day (the medicament us method gives effect only in a week).

Triple SCENAR application throughout a day on the sympathetic innervations in animals rapidly improves the general condition, temperature returns to norm, inflammatory process in a uterus is blocked, and the motility is normal. In 1.5 hours strong discharge from a uterus begins, in 3 hours discharge becomes mucous/ slimy/ mucilaginous, and in 10-12 hours it stops Duringt rectal inspection the uterus moves to pelvic cavity, and is rigid. The strong inflammation of external genitals is removed in 2.5 hours.

During SCENAR therapy the phagocytic activity of leukocytes increases. On the second day of the treatment the phagocytic index of segment-nuclear neutrophils significantly increases in 3-5 times. An interesting fact to mention that a hyperactivity of leukocytes is high for 10-15 day.

Using traditional methods of treatment allows to slightly increase a phagocytic index, and on the 5th day the activity decreases to an initial level slightly. Application of SCENAR therapy in many cases will allow to avoid surgical intervention and to significantly reduce the use of medicines to raise therapeutic and economic efficiency of treatment of mastitis and endometritis in productive cows and also to reduce antibiotics adaptation. Researchers found no side effects during SCENAR therapy.

Bibliography:
V.V.Chernyshev and others. Users Manual to the Devices of Electric Neuro-Adaptive Therapy “DENAS” and “SCENAR-032-1” – Yekaterinburg: 2002. – 238p.
A.D.Polyakov, V.N.Stepanov SCENAR Therapy for Treatment and Prophylaxis of Cattle’s Diseases/ KemAgrIns. – Kemerovo, 2002. – 68 p.

The Efficacy of SCENAR Therapy for Myofascial Pain Syndrome

The Efficacy of SCENAR Therapy for Myofascial Pain Syndrome

In Bo Han, MD, Ji Young Moon, MD, Ryoong Huh, MD, Hye Young Yoo, RN, Sang Sup Chung, MD
Department of Neurosurgery, Bundang CHA hospital, Pochon CHA University, Sungnam, Korea
Corresponding author Ryoong Huh, M.D.
Department of Neurosurgery, Pochon CHA University, College of Medicine, Bundang CHA Hospital, 351, Yatap-dong, Bundang-Gu, Sungnam, 463-712, Korea Tel: +82-31-780-5260 Fax: +82-31-780-5269 E-mail : hrnsd@hanmail.net
Running Head: SCENAR Therapy

ABSTRACT

Objectives: Myofascial pain syndrome (MPS) is a frequent cause of chronic musculoskeletal pain.

The purpose of this study is to verify the usefulness of SCENAR standing for Self-Controlled Energo-Neuro-Regulator in patients with MPS.

Materials and Methods: We retrospectively analyzed 340 patients from March 2006 to December 2006 in whom SCENAR therapy was performed for MPS. SCENAR therapy consisted in 10 sessions lasting 20 minutes. Therapeutic effects were evaluated before treatment, at 1 week, and at month after the end of treatment using a visual analogue scale (VAS) and we categorized treatments as effective or ineffective.
Results: The patients treated by SCENAR therapy showed significant improvement in the VAS. One week after the SCENAR therapy, 296 patients (87.2 %) had experienced effective pain relief, and these improvements were maintained at the 1 month follow-up evaluation.

Conclusion: SCENAR therapy is a safe and effective means of treating patients with MPS.

KEYWORDS: Myofascial pain syndrome • pain • SCENAR

DOWNLAOD